Aspen Neuroscience has completed the first two cohorts in its ASPIRO Phase 1/2a trial for Parkinson's disease, evaluating ANPD001.

A new study on redosing Diamyd®, an antigen-specific immunotherapy, demonstrates its safety and potential efficacy in preserving beta-cell function in Type 1 Diabetes.

The FDA issued a Complete Response Letter (CRL) for Zealand Pharma's dasiglucagon for congenital hyperinsulinism (CHI) for up to three weeks of dosing.

The SOUL trial demonstrated that oral semaglutide significantly reduces cardiovascular events in type 2 diabetes patients with atherosclerotic cardiovascular and/or chronic kidney disease.

A clinical trial in China evaluated weekly doses of 25mg and 50mg of mifepristone for contraception, demonstrating no pregnancies across 456 women-months of use.

Nimbus Therapeutics has completed its IND submission for NDI-219216, a non-covalent WRN inhibitor, planned for a clinical trial in H1 2025.

BiPER Therapeutics has secured €800,000 in bridge funding to advance its lead candidate, BPR001-615, a first-in-class BiP inhibitor, towards clinical trials.

Shilpa Medicare's Unit VI in Bengaluru has secured Good Manufacturing Practice (GMP) certification from the European Medicines Agency following a successful inspection with only minor observations.

Omilancor, a first-in-class oral LANCL2 agonist in Phase 3 development, demonstrated superior efficacy to anti-TL1A antibodies in treating inflammatory bowel disease with an unrivaled safety profile.

UK-based Thriva has partnered with medical device manufacturer Tasso to develop needle-free blood testing technology, addressing a condition affecting at least 10% of adults and up to 63% of children.

Lumicera Health Services has partnered with Costco to expand cost-plus specialty pharmacy services, providing transparent pricing and enhanced patient support for complex medications.

MIRA Pharmaceuticals' Ketamir-2 shows 60% greater efficacy than gabapentin in reducing chemotherapy-induced neuropathic pain in preclinical studies.

The European Medicines Agency's (EMA) CHMP supports Leqembi's approval for early Alzheimer's, reversing its earlier negative opinion.

Cognition Therapeutics' CT1812 demonstrated a 95% slowing of cognitive decline in Alzheimer's patients with lower plasma p-tau217 levels in Phase 2 SHINE study.

LAVA Therapeutics is implementing significant restructuring, including a 30% workforce reduction and closure of Netherlands operations, while evaluating strategic alternatives to maximize shareholder value.

Ascendis Pharma's Skytrofa revenue missed estimates due to increased sales deductions, leading to a downward revision of FY24 revenue guidance.

Cidara Therapeutics reacquired CD388, a long-acting antiviral drug, from Janssen after Janssen exited infectious disease development.

SK Bioscience has successfully won an appeal against Pfizer's subsidiary Wyeth LLC in a patent dispute over pneumococcal vaccine components exported to Russia for research purposes.

Fujifilm has successfully validated peptide-oligonucleotide conjugates that selectively target cancer cells, utilizing cyclic peptides from their proprietary library containing trillions of variants.

A recent study highlights significant disparities in race, ethnicity, gender, and geography among participants in clinical trials for FDA-approved IBS therapies.